文献速递心脑血管急症消化、代谢与肾脏急症

埃格列净(Ertugliflozin)在2型糖尿病中的心血管结局

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
PubMed 文献 · N Engl J Med · 2020-09-23
一句话结论在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,埃格列净(5 mg或15 mg每日一次,两剂量合并分析)心血管主要不良事件非劣于安慰剂(HR 0.97,95.6%CI 0.85–1.11)。

VERTIS CV为多中心、双盲试验,纳入8246例2型糖尿病合并动脉粥样硬化性心血管疾病患者,随机接受埃格列净5 mg、15 mg或安慰剂每日一次,两剂量组合并分析,平均随访3.5年。主要终点(心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点)在埃格列净组与安慰剂组发生率均为11.9%(HR 0.97,95.6%CI 0.85–1.11,非劣效P<0.001)。心血管死亡或心力衰竭住院复合终点HR 0.88(95.8%CI 0.75–1.03,优效性P=0.11)。

要点

  • 2型糖尿病合并动脉粥样硬化性心血管疾病患者,埃格列净5 mg或15 mg每日一次(两剂量合并)主要心血管不良事件非劣于安慰剂(HR 0.97,95.6%CI 0.85–1.11)。
  • 心血管死亡或心衰住院复合终点:埃格列净组8.1% vs 安慰剂组9.1%(HR 0.88,95.8%CI 0.75–1.03,优效性P=0.11)。
  • 心血管死亡:HR 0.92(95.8%CI 0.77–1.11);肾脏死亡、肾脏替代治疗或血清肌酐翻倍复合终点:HR 0.81(95.8%CI 0.63–1.04)。
  • 截肢:埃格列净5 mg组2.0%(54例),15 mg组2.1%(57例),安慰剂组1.6%(45例)。

适用人群与场景

  • 2型糖尿病合并动脉粥样硬化性心血管疾病患者,年龄及性别等基线特征原文未报告。

处置流程与药物剂量

  • 埃格列净5 mg或15 mg每日一次口服,与安慰剂比较,两剂量组合并分析,平均随访3.5年。
  • 主要心血管不良事件定义为心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点。

研究设计与关键结果

  • 研究类型:多中心、双盲、安慰剂对照试验;8246例随机,8238例至少接受一剂研究药物。
  • 主要终点(心血管死亡、非致死性心肌梗死或非致死性卒中):埃格列净组653/5493例(11.9%)vs 安慰剂组327/2745例(11.9%),HR 0.97(95.6%CI 0.85–1.11),非劣效P<0.001。
  • 关键次要终点(心血管死亡或心力衰竭住院):埃格列净组444/5499例(8.1%)vs 安慰剂组250/2747例(9.1%),HR 0.88(95.8%CI 0.75–1.03),优效性P=0.11。
  • 心血管死亡:HR 0.92(95.8%CI 0.77–1.11)。
  • 肾脏死亡、肾脏替代治疗或血清肌酐翻倍复合终点:HR 0.81(95.8%CI 0.63–1.04)。
  • 截肢:5 mg组54例(2.0%),15 mg组57例(2.1%),安慰剂组45例(1.6%)。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机对照试验(VERTIS CV,NCT01986881)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对2型糖尿病合并动脉粥样硬化性心血管疾病患者,埃格列净5 mg或15 mg每日一次在主要心血管不良事件上非劣于安慰剂(HR 0.97,95.6%CI 0.85–1.11)。
  • 心血管死亡或心衰住院复合终点、心血管死亡、肾脏复合终点均未达统计学显著(HR 0.88,95.8%CI 0.75–1.03;HR 0.92,95.8%CI 0.77–1.11;HR 0.81,95.8%CI 0.63–1.04)。
  • 截肢发生率:埃格列净5 mg组2.0%、15 mg组2.1%,安慰剂组1.6%。

指南或共识出处

  • VERTIS CV(ClinicalTrials.gov NCT01986881),由Merck Sharp & Dohme和Pfizer资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.

METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.

RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo.

CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020. PMID: 32966714. doi:10.1056/NEJMoa2004967

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。